Harald Fricke

Apogenix (Germany) — Germany

Immunology and Microbiology · Life Sciences

17h-index1.0kcitations54works3.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(12), Cardiac Imaging and Diagnostics(9), Monoclonal and Polyclonal Antibodies Research(9), Glioma Diagnosis and Treatment(8), Cancer Immunotherapy and Biomarkers(8)

Publications54 total

Efficacy and safety of asunercept, a CD95L-selective inhibitor, in hospitalised patients with moderate-to-severe COVID-19: ASUNCTIS, a multicentre, randomised, open-label, controlled, phase 2 trial
EClinicalMedicine·2024· 3 citedOpen Access
Longitudinal analysis of quality of life following treatment with Asunercept plus reirradiation versus reirradiation in progressive glioblastoma patients
Journal of Neuro-Oncology·2019· 19 citedOpen Access
HERA-GITRL activates T cells and promotes anti-tumor efficacy independent of FcγR-binding functionality
Journal for ImmunoTherapy of Cancer·2019· 32 citedOpen Access
Abstract 5015: HERA-CD40L a hexavalent CD40 agonist induces T cell mediated anti-tumor immune response and shows superior activity in direct comparison to benchmark agonistic antibodies
Cancer Research·2019· 2 cited
Abstract 4845: HERA-CD27L, a true CD27 agonist, is a hexavalent CD27 ligand that enhances T cell activation and induces potent anti-tumor immunity
Cancer Research·2019· 2 cited
Translational PBPK Modeling of the Protein Therapeutic and CD95L Inhibitor Asunercept to Develop Dose Recommendations for Its First Use in Pediatric Glioblastoma Patients
Pharmaceutics·2019· 19 citedOpen Access
The Hexavalent CD40 Agonist HERA-CD40L Induces T-Cell–mediated Antitumor Immune Response Through Activation of Antigen-presenting Cells
Journal of Immunotherapy·2018· 28 cited
A Single-Chain-Based Hexavalent CD27 Agonist Enhances T Cell Activation and Induces Anti-Tumor Immunity
Frontiers in Oncology·2018· 20 citedOpen Access
Abstract 630: Novel hexavalent HVEM agonist HERA-LIGHT promotes T cell activation and expansion
Cancer Research·2018
The novel TRAIL-receptor agonist APG350 exerts superior therapeutic activity in pancreatic cancer cells
Cell Death and Disease·2018· 39 citedOpen Access
Safety and efficacy of the CD95-ligand inhibitor asunercept in transfusion-dependent patients with low and intermediate risk MDS
Leukemia Research·2018· 15 cited
Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma
Molecular Cancer Research·2018· 34 citedOpen Access
Abstract 1688: HERA-CD40L: A novel hexavalent CD40 agonist with superior biological activity
Cancer Research·2017
Abstract 4963: Novel hexavalent GITR agonists stimulate T cells and enhance memory formation
Cancer Research·2017
Abstract 4690: Hexavalent CD27 agonists show single agent anti-tumor activity and enhanced memory formation in mouse syngeneic tumor models
Cancer Research·2017
Abstract A83: Hexavalent agonists targeting co-stimulatory receptors of the tumor necrosis factor superfamily
Cancer Immunology Research·2017
Abstract B48: Structure to function: comparison of CD40 agonist formats reveals superior immune-modulating properties of hexavalent scCD40L-RBD-Fc fusion protein APG1233
Cancer Immunology Research·2017
Abstract B066: The hexavalent CD40 agonist APG1233 is a superior inducer of immune cell activation compared to trimeric formats or agonistic anti-CD40 antibodies
Cancer Immunology Research·2016
Identification of an epigenetic biomarker predicting the response to therapy with APG101 in glioblastoma
Annals of Oncology·2016Open Access
Abstract 1204: A construction platform for hexavalent agonists targeting receptors of the tumor necrosis factor superfamily: Where death meets co-stimulation
Cancer Research·2016· 1 cited
page 1 of 3Next →

Frequent Co-authors

Christian Gieffers(21), Christian J. Merz(19), Meinolf Thiemann(18), Jaromir Sykora(17), Oliver Hill(17), Wolfgang Burchert(14), E. Fricke(12), David M. Richards(11), Claudia Kunz(10), Michael Kluge(10), Oliver Lindner(10), R. Weise(9), Viola Marschall(9), Karl Heinonen(8), Wolfgang Wick(6), Mauricio Redondo Müller(6), Annett Kammeier(5), Julian P. Sefrin(5), Siegfried Eckert(4), Dieter Horstkotte(4)